Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 20, 2019 - Issue 15
Submit an article Journal homepage
2,349
Views
11
CrossRef citations to date
0
Altmetric
Editorial

Key considerations in the pharmacotherapy of tuberculous meningitis

Sean WassermanWellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa;Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, South AfricaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-3508-6719View further author information
ORCID Icon,
Angharad DavisWellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa;Faculty of Life Sciences, University College London, London, UK;The Francis Crick Institute, London, UKView further author information
,
Robert J. WilkinsonWellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa;The Francis Crick Institute, London, UK;Department of Medicine, Imperial College London, London, UKView further author information
&
Graeme MeintjesWellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa;Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, South AfricaView further author information
Pages 1791-1795 | Received 22 May 2019, Accepted 28 Jun 2019, Published online: 15 Jul 2019

References

  • Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nature Rev Neurol. 2017;13:581–598.
  • Marais S, Pepper DJ, Marais BJ, et al. HIV-associated tuberculous meningitis–diagnostic and therapeutic challenges. Tuberculosis (Edinb). 2010;90(6):367–374.
  • Davis A, Meintjes G, Wilkinson RJ. Treatment of tuberculous meningitis and its complications in adults. Curr Treat Options Neurol. 2018;20:5.
  • Dian S, Yunivita V, Ganiem AR, et al. Double-blind, randomized, placebo-controlled phase II dose-finding study to evaluate high-dose rifampin for tuberculous meningitis. Antimicrob Agents Chemother. 2018;62: pii:e01014–18.
  • Yunivita V, Dian S, Ganiem AR, et al. Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients. Int J Antimicrob Agents. 2016;48:415–421.
  • Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13:27–35.
  • Heemskerk AD, Bang ND, Mai NT, et al. Intensified antituberculosis therapy in adults with tuberculous meningitis. N Engl J Med. 2016;374:124–134.
  • Tucker EW, Guglieri-Lopez B, Ordonez AA, et al. Noninvasive 11C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis. Sci Transl Med. 2018;10:eaau0965.
  • Donald PR. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb). 2010;90(5):279–292.
  • van Well GT, Paes BF, Terwee CB, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa. Pediatrics. 2009;123(1):e1–e8.
  • Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother. 2011;55:3244–3253.
  • Heemskerk AD, Nguyen MTH, Dang HTM, et al. Clinical outcomes of patients with drug-resistant tuberculous meningitis treated with an intensified antituberculosis regimen. Clin Infect Dis. 2017;65:20–28.
  • Drusano GL, Myrick J, Maynard M, et al. Linezolid kills acid phase and non-replicative persister phase mycobacterium tuberculosis in a hollow fiber infection model. Antimicrob Agents Chemother. 2018;62: pii:e00221–18.
  • Drusano GL, Neely M, Van Guilder M, et al. Analysis of combination drug therapy to develop regimens with shortened duration of treatment for tuberculosis. PloS One. 2014;9:e101311.
  • Li H, Lu J, Liu J, et al. Linezolid is associated with improved early outcomes of childhood tuberculous meningitis. Pediatr Infect Dis J. 2016;35:607–610.
  • Sun F, Ruan Q, Wang J, et al. Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis. Antimicrob Agents Chemother. 2014;58:6297–6301.
  • Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4:Cd002244.
  • Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell. 2012;148:434–446.
  • Mai NT, Dobbs N, Phu NH, et al. A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults. eLife. 2018;7: pii:e33478.
  • Misra UK, Kalita J, Nair PP. Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci. 2010;293:12–17.
  • Schoeman JF, Janse van Rensburg A, Laubscher JA, et al. The role of aspirin in childhood tuberculous meningitis. J Child Neurol. 2011;26:956–962.
  • Schoeman JF, Springer P, Ravenscroft A, et al. Adjunctive thalidomide therapy of childhood tuberculous meningitis: possible anti-inflammatory role. J Child Neurol. 2000;15:497–503.
  • Schoeman JF, Springer P, van Rensburg AJ, et al. Adjunctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol. 2004;19:250–257.
  • Wasserman S, Meintjes G, Maartens G. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index. Expert Rev Anti Infect Ther. 2016;14:901–915.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.